A compatible gravity-driven organoid perfusion (GDOP) platform for drug screening with sensitivity and toxicity process evaluation

  • Commun Biol. 2026 Apr 2;9(1):718. doi: 10.1038/s42003-026-09973-5.
Shun Wang  1 ,  Xiaoliang Zhang  1 ,  Houshi Ma  1 ,  Linlin Lu  2 ,  Huabin Jiang  3 ,  Yuqiao Bai  4 ,  Xiaoran Chang  1 ,  Jinxian Wang  5  6 ,  Tianhang Yang  7  8 ,  Gangyin Luo  9  10
Affiliations
  • 1. Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.
  • 2. The First Affiliated Hospital of Soochow University, Suzhou, China.
  • 3. College of Life Sciences, Shandong Normal University, Jinan, China.
  • 4. School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • 5. Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China. [email protected].
  • 6. School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. [email protected].
  • 7. Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China. [email protected].
  • 8. Jinan Guoke Medical Technology Development Co. Ltd, Jinan, China. [email protected].
  • 9. Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China. [email protected].
  • 10. School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. [email protected].
PMID: 41922471 DOI: 10.1038/s42003-026-09973-5
Abstract

High-throughput experiments, unidirectional fluid replacement, real-time process monitoring, and simultaneous drug sensitivity and toxicity tests are hard to achieve on most existing tumor Organoid chips. Here, we developed a gravity-driven Organoid perfusion (GDOP) platform facilitating scalable throughput and supporting drug sensitivity and toxicity assessment on organoids. The unidirectional perfusion capability and optimized operational parameters of the GDOP chip were validated through fluid dynamics simulations. Using this platform, we successfully established uniform on-chip triple-negative breast Cancer (TNBC) organoids, with endpoint detection results aligning closely with clinical diagnosis. Throughout the drug treatment process, we monitored and then analyzed the morphological and grayscale changes of the organoids. The sensitivity and toxicity tests revealed the optimal concentration range for the 3 chemotherapeutic drugs. In addition, on-chip brain organoids were established, which lays a feasible foundation for future drug toxicity tests of complex organoids. The GDOP platform, combined with its integrated evaluation method, provides a powerful and reliable approach for advancing organoid-based researches.

Products